"That was Pipex (PP), not Cortex (COR)."
COR does, however, have a number of ampakine candidates listed as potential AD treatments. I have tracked COR for years and would say, just on watching the share value that they have ineffective management.
I see little chance that any of their candidates will ever reach the market.
BTW, for whatever reason, I see PPHM as a similar co. from a market and mgmt standpoint. They hit my radar at just about the same time (both were co.s touted in the physician's lounge by one or another investing Dr.) and both have done little over the course of 6 years to provide any reason to invest, IMO.
aj
